Latest News for TTRX
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, toda
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with…
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and six months ended June 30, 2026. “The second quarter was one of the most productive periods in Turn Therapeutics' history. Our…
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for TTRX.
Senate Trading
No Senate trades found for TTRX.
U.S. House Trading
No House trades found for TTRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.